Short Interest in Immutep Limited (NASDAQ:IMMP) Increases By 5.1%

Immutep Limited (NASDAQ:IMMP) saw a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 3,920,000 shares, a growth of 5.1% from the May 15th total of 3,730,000 shares. Based on an average trading volume of 234,100 shares, the short-interest ratio is presently 16.7 days.

Wall Street Analysts Forecast Growth

Separately, Capital One Financial started coverage on Immutep in a research note on Friday, May 17th. They issued an “overweight” rating and a $10.00 price target for the company.

Immutep Trading Down 4.5 %

Shares of IMMP opened at $2.57 on Thursday. Immutep has a 52 week low of $1.58 and a 52 week high of $3.34. The stock has a fifty day moving average of $2.73 and a 200-day moving average of $2.49.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Virtu Financial LLC raised its position in Immutep by 269.4% during the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares during the last quarter. Oracle Investment Management Inc. raised its position in Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock worth $1,316,000 after purchasing an additional 48,449 shares during the last quarter. BNP Paribas Financial Markets raised its position in Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 4,700 shares during the last quarter. PFG Investments LLC bought a new position in Immutep during the 1st quarter worth $119,000. Finally, Meridian Wealth Management LLC raised its position in shares of Immutep by 3.6% in the 4th quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock worth $774,000 after acquiring an additional 11,250 shares in the last quarter. 2.32% of the stock is owned by institutional investors.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.